Literature DB >> 16847318

The normal phenotype of Pmm1-deficient mice suggests that Pmm1 is not essential for normal mouse development.

K Cromphout1, W Vleugels, L Heykants, E Schollen, L Keldermans, R Sciot, R D'Hooge, P P De Deyn, K von Figura, D Hartmann, C Körner, G Matthijs.   

Abstract

Phosphomannomutases (PMMs) are crucial for the glycosylation of glycoproteins. In humans, two highly conserved PMMs exist: PMM1 and PMM2. In vitro both enzymes are able to convert mannose-6-phosphate (mannose-6-P) into mannose-1-P, the key starting compound for glycan biosynthesis. However, only mutations causing a deficiency in PMM2 cause hypoglycosylation, leading to the most frequent type of the congenital disorders of glycosylation (CDG): CDG-Ia. PMM1 is as yet not associated with any disease, and its physiological role has remained unclear. We generated a mouse deficient in Pmm1 activity and documented the expression pattern of murine Pmm1 to unravel its biological role. The expression pattern suggested an involvement of Pmm1 in (neural) development and endocrine regulation. Surprisingly, Pmm1 knockout mice were viable, developed normally, and did not reveal any obvious phenotypic alteration up to adulthood. The macroscopic and microscopic anatomy of all major organs, as well as animal behavior, appeared to be normal. Likewise, lectin histochemistry did not demonstrate an altered glycosylation pattern in tissues. It is especially striking that Pmm1, despite an almost complete overlap of its expression with Pmm2, e.g., in the developing brain, is apparently unable to compensate for deficient Pmm2 activity in CDG-Ia patients. Together, these data point to a (developmental) function independent of mannose-1-P synthesis, whereby the normal knockout phenotype, despite the stringent conservation in phylogeny, could be explained by a critical function under as-yet-unidentified challenge conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847318      PMCID: PMC1592770          DOI: 10.1128/MCB.02357-05

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  29 in total

1.  Cerebellar atrophy: an important feature of carbohydrate deficient glycoprotein syndrome type 1.

Authors:  H Antoun; N Villeneuve; A Gelot; S Panisset; C Adamsbaum
Journal:  Pediatr Radiol       Date:  1999-03

2.  Comparison of PMM1 with the phosphomannomutases expressed in rat liver and in human cells.

Authors:  M Pirard; J F Collet; G Matthijs; E Van Schaftingen
Journal:  FEBS Lett       Date:  1997-07-14       Impact factor: 4.124

3.  Developmental patterns and neuropsychological assessment in patients with carbohydrate-deficient glycoconjugate syndrome type IA (phosphomannomutase deficiency).

Authors:  R Barone; L Pavone; A Fiumara; R Bianchini; J Jaeken
Journal:  Brain Dev       Date:  1999-06       Impact factor: 1.961

4.  Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2.

Authors:  M Pirard; G Matthijs; L Heykants; E Schollen; S Grünewald; J Jaeken; E van Schaftingen
Journal:  FEBS Lett       Date:  1999-06-11       Impact factor: 4.124

5.  Kinetic properties and tissular distribution of mammalian phosphomannomutase isozymes.

Authors:  M Pirard; Y Achouri; J F Collet; E Schollen; G Matthijs; E Van Schaftingen
Journal:  Biochem J       Date:  1999-04-01       Impact factor: 3.857

6.  Protein C-mannosylation is enzyme-catalysed and uses dolichyl-phosphate-mannose as a precursor.

Authors:  M A Doucey; D Hess; R Cacan; J Hofsteenge
Journal:  Mol Biol Cell       Date:  1998-02       Impact factor: 4.138

7.  Hypoglycosylation of a brain glycoprotein (beta-trace protein) in CDG syndromes due to phosphomannomutase deficiency and N-acetylglucosaminyl-transferase II deficiency.

Authors:  S Pohl; A Hoffmann; A Rüdiger; M Nimtz; J Jaeken; H S Conradt
Journal:  Glycobiology       Date:  1997-12       Impact factor: 4.313

8.  beta-Trace protein in human cerebrospinal fluid: a diagnostic marker for N-glycosylation defects in brain.

Authors:  S Grünewald; K Huyben; J G de Jong; J A Smeitink; E Rubio; G H Boers; H S Conradt; U Wendel; R A Wevers
Journal:  Biochim Biophys Acta       Date:  1999-09-20

Review 9.  Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies.

Authors:  J N Crawley; J K Belknap; A Collins; J C Crabbe; W Frankel; N Henderson; R J Hitzemann; S C Maxson; L L Miner; A J Silva; J M Wehner; A Wynshaw-Boris; R Paylor
Journal:  Psychopharmacology (Berl)       Date:  1997-07       Impact factor: 4.530

10.  Comparative analysis of the phosphomannomutase genes PMM1, PMM2 and PMM2psi: the sequence variation in the processed pseudogene is a reflection of the mutations found in the functional gene.

Authors:  E Schollen; E Pardon; L Heykants; J Renard; N A Doggett; D F Callen; J J Cassiman; G Matthijs
Journal:  Hum Mol Genet       Date:  1998-02       Impact factor: 6.150

View more
  18 in total

1.  A deeply divergent phosphoglucomutase (PGM) of Giardia lamblia has both PGM and phosphomannomutase activities.

Authors:  Sanghamitra Mitra; Jike Cui; Phillips W Robbins; John Samuelson
Journal:  Glycobiology       Date:  2010-05-27       Impact factor: 4.313

2.  Ontogeny of D-mannose transport and metabolism in rat small intestine.

Authors:  Mecedes Cano; Anunciación A Ilundain
Journal:  J Membr Biol       Date:  2010-06-04       Impact factor: 1.843

3.  Molecular cloning and functional analysis of the phosphomannomutase (PMM) gene from Dendrobium officinale and evidence for the involvement of an abiotic stress response during germination.

Authors:  Chunmei He; Songjun Zeng; Jaime A Teixeira da Silva; Zhenming Yu; Jianwen Tan; Jun Duan
Journal:  Protoplasma       Date:  2016-12-16       Impact factor: 3.356

4.  Targeted disruption of the mouse phosphomannomutase 2 gene causes early embryonic lethality.

Authors:  Christian Thiel; Torben Lübke; Gert Matthijs; Kurt von Figura; Christian Körner
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

5.  Evolutionary history and functional diversification of phosphomannomutase genes.

Authors:  Rita Quental; Ana Moleirinho; Luísa Azevedo; António Amorim
Journal:  J Mol Evol       Date:  2010-07-27       Impact factor: 2.395

6.  Mammalian phosphomannomutase PMM1 is the brain IMP-sensitive glucose-1,6-bisphosphatase.

Authors:  Maria Veiga-da-Cunha; Wendy Vleugels; Pushpa Maliekal; Gert Matthijs; Emile Van Schaftingen
Journal:  J Biol Chem       Date:  2008-10-16       Impact factor: 5.157

Review 7.  Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients.

Authors:  Hudson H Freeze
Journal:  Biochim Biophys Acta       Date:  2009-09

8.  Molecular analysis of phosphomannomutase (PMM) genes reveals a unique PMM duplication event in diverse Triticeae species and the main PMM isozymes in bread wheat tissues.

Authors:  Chunmei Yu; Yiwen Li; Bin Li; Xin Liu; Lifang Hao; Jing Chen; Weiqiang Qian; Shiming Li; Guanfeng Wang; Shiwei Bai; Hua Ye; Huanju Qin; Qianhua Shen; Liangbiao Chen; Aimin Zhang; Daowen Wang
Journal:  BMC Plant Biol       Date:  2010-10-05       Impact factor: 4.215

9.  Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation.

Authors:  Liangwu Sun; Yingjun Zhao; Kun Zhou; Hudson H Freeze; Yun-Wu Zhang; Huaxi Xu
Journal:  Mol Brain       Date:  2013-12-04       Impact factor: 4.041

10.  Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation.

Authors:  Giuseppina Andreotti; Emilia Pedone; Assunta Giordano; Maria Vittoria Cubellis
Journal:  Mol Genet Genomic Med       Date:  2013-03-27       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.